<DOC>
	<DOCNO>NCT01046383</DOCNO>
	<brief_summary>The primary aim IMN 1207 follow-up study confirm effect cysteine-rich non-denatured whey protein isolate formulation IMN1207 ( 20g daily ) versus casein ( 20 g daily ) reversal weight loss ( cancer-related wasting ) 40 week treatment period non-small cell lung cancer patient without conventional therapy , i.e. , chemotherapy radiation . And test hypothesis period 66 week observation period include 6 month follow-up period , increase survival patient .</brief_summary>
	<brief_title>Effect IMN1207 Versus Casein Weight Loss , Survival Quality Life Non-small Cell Lung Cancer Patients</brief_title>
	<detailed_description>This new IMN 1207 study follow-up study first IMN 1207 trial sponsor Immunotec Inc last 3 year . The study reveal cysteine-rich whey protein isolate formulation IMN 1207 cause significant reversal weight loss ( P &lt; 0.05 ) conspicuous increase survival . The outcome first IMN 1207 study publish ( Tozer RG , et al . Cysteine-Rich Protein Reverses Weight Loss Lung Cancer Patients Receiving Chemotherapy Radiotherapy . Antioxid Redox Signal . 2008 Feb ; 10 ( 2 ) :395-402 ) . PMID:18158761 . The purpose IMN 1207 follow-up study confirm effect cysteine-rich non-denatured whey protein isolate formulation IMN1207 ( 20g daily ) versus casein ( 20 g daily ) reversal weight loss ( cancer-related wasting ) 40 week treatment period non-small cell lung cancer subject without conventional therapy , i.e. , chemotherapy radiation . In addition , prospectively design test hypothesis , IMN1207 versus casein period 66 week observation period include 6 month follow-up period , increase survival subject . Also , effect IMN1207 quality life define subgroup subject determine .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Caseins</mesh_term>
	<criteria>Non small cell lung cancer stage III stage IV . Karnofsky performance status great equal 70 % . Expected participation study 3 month . Involuntary decrease body weight 3 % 15 month period immediately precede study entry . Age 18 old . Serum creatine less equal 3.0mg/dL 265 Âµmol/L . Total bilirubin normal range ( 0.21.2 mg/dL ) SGPT equal le 4 time upper limit normal . Reliable contraception ( ovariectomy , hysterectomy , tubuligation least six month , oral contraceptive , barrier method , etc . ) woman child bear potential . History angioedema allergic reaction compound employ study . Pregnancy lactate . Uncontrolled metastatic brain tumor . Milk protein intolerance . Subjects currently use Nacetylcysteine , alphalipoic acid supplement , dry whey protein supplement . Presence ascitis edema accord principle investigator 's clinical judgment . Significant anemia , define requirement treatment EPO . Subjects either mild soy allergy/intolerance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>NON-SMALL CELL LUNG CANCER PATIENTS</keyword>
	<keyword>WEIGHT LOSS</keyword>
	<keyword>QUALITY OF LIFE</keyword>
	<keyword>SURVIVAL</keyword>
	<keyword>CHEMOTHERAPY</keyword>
	<keyword>RADIOTHERAPY</keyword>
	<keyword>SURGERY</keyword>
	<keyword>CYSTEINE-RICH WHEY PROTEIN ISOLATE</keyword>
	<keyword>IMN1207</keyword>
	<keyword>CANCER-RELATED WASTING ( CACHEXIA )</keyword>
	<keyword>BODY WEIGHT</keyword>
	<keyword>NUTRITIONAL PROTEIN SUPPLEMENT</keyword>
</DOC>